Key takeaways

  • Haleon is a FTSE 100 and FTSE 350 stock, dual-listed in London and New York under the ticker HLN.
  • The Board proposed a 2024 total Dividend of 6.6p per ordinary share, comprising a final dividend of 4.6p paid on 5 June 2025, representing a Payout Ratio of approximately 37% of 2024 adjusted Earnings.
  • Haleon has continued an active share buyback programme through 2025, with transactions reported at weighted average prices in the 358p to 379p range.
  • The company is a global consumer healthcare leader with brands including Sensodyne, Panadol, Advil, Centrum and Voltaren.
  • Key risks include consumer Demand pressure, FX, regulation and competition.

Introduction: Why Haleon shares are in focus on the FTSE 350

Haleon plc (LSE:HLN) is one of the newest names on the FTSE 100, having been spun off from GSK in 2022. Today, it is one of the world’s largest pure-play consumer healthcare companies, with a portfolio of household brands that include Sensodyne, Panadol, Centrum, Advil and Voltaren. As both a FTSE 100 and FTSE 350 constituent, Haleon attracts attention from UK investors looking for defensive, branded consumer exposure on the London Stock Exchange.

The Haleon share price has been in focus throughout 2025 and 2026, as investors digest the company’s 2024 full-year results, ongoing share buyback activity and progress on its post-demerger strategy. With consumer healthcare often seen as a defensive sector, Haleon is closely watched by UK income and quality investors. For FTSE 350 watchers, it is one of the largest and most strategically important consumer health stocks in the index.

Company overview: A global consumer health leader

Haleon is the consumer healthcare Business that was previously part of GlaxoSmithKline plc and Pfizer’s consumer health Partnership. After being demerged from GSK in 2022, the company is now an independent listed entity, headquartered in the UK and trading on the LSE and NYSE under the ticker HLN. Its product portfolio spans six major categories: Oral Health, Vitamins, Minerals and Supplements (VMS), Pain Relief, Respiratory Health, Digestive Health and Therapeutic Skin Health, plus an “Other” category. Brands include Advil, Centrum, Otrivin, Panadol, parodontax, Polident, Sensodyne, Theraflu and Voltaren.

Haleon is a constituent of the FTSE 100 and FTSE 350, putting it among the largest UK-listed stocks. For UK investors, Haleon offers exposure to a defensive consumer healthcare business with global Brand power, recurring demand and a focus on health and self-care.

What happened: 2024 full-year results and dividend

The most material recent event for Haleon was the publication of its preliminary 2024 full-year results on 27 February 2025. According to publicly available announcements, the Board proposed a 2024 total dividend of 6.6p per ordinary share, including a final dividend of 4.6p per share. The final dividend was scheduled to be paid on 5 June 2025 to holders of ordinary shares and US American Depositary Shares on the register as of 25 April 2025. The payout ratio was disclosed at approximately 37% of 2024 adjusted earnings, in line with the company’s policy of progressive returns.

Haleon has also been an active executor of share Buybacks. Publicly disclosed transactions during 2025 took place at weighted average prices in the range of around 358p to 379p across periods between March and September 2025. The PDF snapshot from the FTSE 350 constituent table showed a price of 342.30p, broadly consistent with the trading range in late 2025 and 2026.

Why it matters for UK investors

Haleon matters for UK investors because it provides exposure to a defensive global consumer healthcare leader with a London listing. For UK Blue-Chip and income strategies, Haleon’s combination of brand strength, geographic Diversification and progressive distributions sits alongside other FTSE 100 consumer staples such as Unilever, Reckitt and Diageo.

The Haleon share price is also seen as a barometer for consumer healthcare sentiment in the UK and globally. Movements in the stock are influenced by results, dividend announcements, broader sector trends and the pace of share buybacks.

Latest verified update

The most material verified updates for Haleon include the 2024 full-year results, the 2024 total dividend of 6.6p, ongoing share buyback transactions through 2025 and updates on strategic priorities. Investors should consult Haleon’s Investor relations website and RNS announcements for the most current verified facts on results, dividends and Capital returns.

Share price and investor sentiment

The Haleon share price has reflected a combination of consumer health sector dynamics, dividend and buyback activity, and broader Equity market conditions. According to publicly available data, the stock has traded broadly between around 340p and the high 370p range during 2025.

Investor sentiment in 2025 and 2026 has been shaped by the company’s progress in establishing itself as an independent business following the GSK demerger. Supporters point to strong brands, geographic reach and the defensive nature of consumer health demand. Critics highlight slower Volume growth in some categories, currency headwinds and competition from generics and private label.

Sector and macro context: Consumer healthcare and self-care

The global consumer healthcare sector benefits from long-term structural drivers including ageing populations, growing focus on self-care and rising health awareness in emerging markets. These trends support recurring demand for over-the-counter (OTC) medicines, vitamins and oral health products, even in weaker economic environments.

Macro factors are also important. Inflation has affected input costs and pricing strategies, while consumer income pressure has influenced trade-up and trade-down behaviour across categories and geographies. Currency moves matter because Haleon reports in sterling but generates much of its Revenue in US dollars, euros and other currencies. Regulatory changes around OTC products, Advertising and ingredient approvals are also relevant.

Earnings, dividends and Balance Sheet

According to publicly available results, Haleon’s 2024 financial performance supported a 6.6p total dividend with a payout ratio of approximately 37% of adjusted earnings. The company has emphasised progressive Shareholder returns alongside continued Investment in core brands and innovation.

Haleon has also been working to reduce Leverage following the demerger from GSK. Share buybacks have been a feature of capital allocation through 2025. Investors should follow the company’s investor relations communications for the most current guidance on leverage, capital allocation and dividend policy.

Broker, analyst and investor sentiment

Haleon is widely covered by global analysts and held by major institutional investors. Sentiment in 2025 and 2026 has been shaped by debates over volume growth, pricing power and the value-creation potential of focused consumer healthcare versus broader consumer staples conglomerates.

For specific ratings or price targets, investors should consult their own Brokers or platforms such as Reuters, Bloomberg, the Financial Times, MarketWatch and Yahoo Finance UK. This article does not present specific broker views that cannot be independently verified.

Growth catalysts

Several catalysts could support Haleon’s investment case. The first is Long-term Growth in self-care and consumer healthcare in both developed and emerging markets. The second is innovation across brands such as Sensodyne, Centrum and Voltaren, where pricing power and category Leadership can support margins. The third is operational improvement post-demerger, including cost optimisation and Supply chain efficiency.

Continued share buybacks and a progressive dividend may also support per-share metrics over time.

Risks and uncertainties

Risks include consumer demand pressure in markets where households are trading down, competitive pressure from private label and generics, currency Volatility, regulatory changes and brand-specific issues. The post-demerger leverage profile, while improving, is also a consideration for investors weighing dividends, buybacks and capital flexibility.

What investors should watch next

UK investors monitoring the Haleon share price and FTSE 350 news may want to track upcoming half-year and full-year results, dividend declarations, buyback progress and trading updates. Macro factors including currency moves, inflation and consumer spending will also be relevant. Investors should also follow brand-level commentary on key franchises such as Sensodyne, Centrum and Voltaren.

Conclusion

Haleon is one of the largest pure-play consumer healthcare companies in the world and a FTSE 100 and FTSE 350 constituent on the London Stock Exchange. The 2024 full-year results, the 6.6p total dividend and ongoing share buybacks all underpin the investment case as a defensive consumer brand with global reach. Risks remain around consumer demand, currency and competition, but the long-term self-care trend is a powerful tailwind. For UK investors watching FTSE 350 share price news, Haleon is a key name to follow.